Detail akcie Harbor online

Business Summary: Harbor Biosciences, Inc. (Harbor Biosciences), formerly Harbor Diversified Inc., is a clinical-stage pharmaceutical company. It is engaged in the discovery and development of products for the treatment of diseases that typically onset with age. It is primarily focused on the development of a series of hormone-related sterols that are derived from the human adrenal metabolome. The Company is development-stage company with two product candidates: Apoptone (HE3235) in patients with late-stage prostate cancer, and Triolex (HE3286) in obese type-2 diabetes mellitus patients. The Company focuses on the development of synthetic sterol derivatives derived from the human 19-carbon steroid scaffold of the mammalian sterol metabolome. It has conducted clinical trials with its drug development candidates, which include Apoptone (HE3235); Triolex (HE3286); Neumune (HE2100), for the treatment of sepsis, and HE2000, for the prevention of opportunistic infections in immune-suppressed patients.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2011, Harbor Diversified Inc revenues increased from $0K to $146K. Net loss decreased 42% to $3.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development R & D operating decrease of 50% to $1.9M (expense), Loss on disposition of assets increase from $83K (expense) to $14K (income).